The researchers presented the results of clinical trials of Octagam immunoglobulin, which was effective in the treatment of critically ill patients with COVID-19. This is reported in a press release on EurekAlert!.
The study involved 33 patients with COVID-19, suffering from hypoxia, which required mechanical ventilation (ALV). It turned out that immunoglobulin, which was administered intravenously to the patient, significantly reduced the severity of hypoxia, reduced the length of hospital stay and the risk of the need to switch to mechanical ventilation.
A larger, randomized, double-blind, placebo-controlled study of the drug is currently underway. The main goal of the test is to determine whether high doses of immunoglobulin are able to slow or stop the deterioration of respiratory function in patients with a complication of coronavirus disease. In addition, it will test whether the drug affects the health of patients by improving lung function and correspondingly affecting metabolic factors.